3[3]CAPTURE investigators:Randomized placebo controlled trail of abciximab before and during coronary intervention in refractory unstable angina:Lancet,1997,349(9118):1429.
4[4]Anonymous:Randomized placebo controlled and ballon angioplasty controlled trail to assess safety of coronary glycoprotein Ⅱb/Ⅲa blockade.
5[5]Braunwald.E,Autman.E,Beasley J,et al.ACC/AHA guideling for the management of patients with unstable angina and non ST-Segment elevation myocardial infarction.J Am Coll.
6Iakovou I,Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents[J]. JAMA,2005,293(17) :2126-2130.
7Kastrati A, Elezi S, Dirsehinger J, et al. Influence of lesion length on restenosis after coronary stent placement[J]. Am J Cardiol, 1999,83(12): 1617-1622.
8Cho L, Topoi EJ,Balog C. et al. Clinical benefit of glyeoprotein Ⅱb/Ⅲa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials.Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP Ⅱb/Ⅲa blockade. Evaluation of Platelet Ⅱb/Ⅲa Inhibitor for Stent[J]. J Am Coll Cardiol, 2000, 36 (2) : 381-386.
9Kuchulakanti P,Rha SW,Satler LF,et al. Impact of major side branch on periprocedural enzyme elevation and long-term outcome in patients undergoing percutaneous coronary intervention and brachytherapy for in-stent restenosis [J]. Am J Cardiol,2004,93(11):1394-1397.
10Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial[J]. JAMA, 2005,293(17) :2109-2117.
